Cavion Inc is a clinical-stage pharmaceutical company based in Charlottesville, VA, with a focus on developing innovative Cav3 modulators for movement disorders and rare pediatric epilepsies. Led by a team of experienced professionals, including founder and CEO Andrew Krouse, Cavion is committed to putting people at the center of their research and development efforts.
The company is currently recruiting subjects for their first neurology clinical trial, the T-CALM trial, which is investigating the use of CX-8998 in essential tremor. With a compassionate culture and a dedication to advancing medical treatments, Cavion is poised to make significant contributions to the field of neurology.
Generated from the website